Navigation Links
Mount Sinai is first in New York state to perform new Alzheimer's imaging test in clinical setting
Date:6/19/2012

The Mount Sinai Medical Center is the first institution in New York State to use in the clinical setting a newly approved imaging technique to detect Alzheimer's disease (AD) in people who are cognitively impaired. Until now, physicians have been limited in their ability to diagnose AD, guided almost exclusively by a patient's mental and behavioral symptoms and family history. The innovative techniquerecently approved by the U.S. Food and Drug Administration (FDA), is not only expected to play a critical role in the diagnosis of AD, but in drug research, and the design of clinical trials leading to a cure.

Under the new procedure, patients are injected with a radioactive agent called florbetapir, which binds to the plaques that are hallmark symptoms of AD. The physician then uses a positron emission tomography (PET) scan to highlight the plaques that are binded to the agent. If a large amount of florbetapir is visualized on the image, the patient may have AD. If no plaques are found, this could eliminate AD as a possible cause of the patient's cognitive impairment.

"Until now, a diagnosis of Alzheimer's disease could only be pathologically confirmed at autopsy," said Samuel Gandy, MD, Professor of Neurology and Psychiatry and Director of the Mount Sinai Center for Cognitive Health and NFL Neurological Center at The Mount Sinai Medical Center. "Coupled with traditional clinical examination, florbetapir is a promising tool in helping confirm the diagnosis of a patient who is dealing with cognitive impairment. While we cannot exclude the presence of very low levels of amyloid, a negative test means that a memory problem is likely due to some other cause."

Alzheimer's disease is one of several possible causes of cognitive decline. Symptoms may overlap with other causes of cognitive impairment including memory loss; loss in visuospatial ability and executive function; and behavioral and language difficulties. The imaging technique will be used as an adjunctive tool with traditional methods of diagnosis to help determine if these symptoms are related to AD and if not, eliminate it as a likely cause of them.

"The approval of this agent by the FDA for PET imaging of the brain, already available at The Mount Sinai Medical Center, marks a significant advance in the evaluation of patients suspected of having or being at risk for Alzheimer's Disease," said Josef Machac, MD, Director of Nuclear Medicine and Professor of Radiology at The Mount Sinai Medical Center. "The principal value of this procedure at this time is in excluding beta-amyloid and Alzheimer's disease as cause for memory or cognitive decline. This can help in patient management, and in clinical trials of investigational therapies to find more effective treatment."

Florbetapir is anticipated to be most useful in the research setting, providing scientists with a tool for measuring the efficacy of certain drugs on patients who present with cognitive impairment or AD. The scan will help determine which patients are appropriate for which trials, which drugs are effective and for what duration, and provide a better assessment for disease progression.

"From a research perspective, this imaging technique is a major advance that will propel us forward in designing clinical trials and determining drug efficacy for this debilitating disease," said Dr. Gandy. "I look forward to using it both in my clinical practice to help diagnose my patients, and in my research on the quest for a cure for Alzheimer's disease."


'/>"/>

Contact: Mount Sinai Press Office
newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related medicine news :

1. Mount Sinai researchers develop a multi-target approach to treating tumors
2. Mount Sinai presents treatment trends, vaccine research, prognosis data at ASCO
3. Great recession reflux amounts to more hunger among seniors
4. David H. Koch donates $10 million to Mount Sinais Jaffe Food Allergy Institute
5. Cedars-Sinai physician definitively links irritable bowel syndrome and bacteria in gut
6. Cedars-Sinai stroke team earns award for improving regions quality of care
7. FirstVitals Health and Wellness, Inc. awarded $4 Million CMS Innovation Grant for Unique Telehealth Diabetes Progam Focused on Glycemic Control and Prevention of Diabetic Foot Complications
8. Family first - caring within UK Bangladeshi and Pakistani communities
9. C-Section Babies May Be More Likely to Fail First Hearing Test
10. Multi-center clinical study intensifies first strike at high-risk cancer in kids
11. The first day of development -- a window to successful pregnancy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... July 20, 2017 , ... Remote ... which their iMedSecure™ comes included with each system installation. RMT’s iMedHD2™ ... remote participants for real-time collaboration and immediate decision-making requirements. While never sharing ...
(Date:7/20/2017)... , ... July 20, 2017 , ... ... **An FDAnews Webinar**, Aug. 9, 2017 — 1:30 p.m. – 3:00 p.m. ET, ... passing inspections and boosting quality. , It’s known as the “CY2016 Annual FDA ...
(Date:7/20/2017)... ... July 20, 2017 , ... With nearly half of all ... solution company VisitorsCoverage Inc. has launched TMQuotes, a new cloud-based solution platform which ... online, under their own brand. The online marketplace bridges the technological gap in ...
(Date:7/20/2017)... ... July 19, 2017 , ... At Creekwood Dental Arts, Drs. Donna G. ... treatment and dental implants in Waco, TX, using the latest dental technology ... by Tekscan®, they can capture details in the oral cavity for accurate diagnoses and ...
(Date:7/20/2017)... Washington (PRWEB) , ... July 19, 2017 , ... ... 11 “surprising habits” that may sometimes lead to, or worsen, varicose veins in ... Aesthetic Center notes that, while avoiding certain not-so-good practices, like excessive sitting or ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... 2017  Eli Lilly and Company (NYSE: LLY ... to resolve pending patent litigation in the U.S. District Court ... regarding the Cialis ® (tadalafil) unit dose patent. This ... As part of the agreement, Cialis exclusivity is now expected ... "The unit dose patent for Cialis is valid and ...
(Date:7/11/2017)... 2017  Bayer has awarded grants totaling more than $2 ... its prestigious Bayer Hemophilia Awards Program (BHAP). Four U.S. clinicians ... and Uniformed Services University of the Health Sciences ... Grant recipients were announced last night during a reception at ... Berlin, Germany . ...
(Date:7/11/2017)... , July 11, 2017  Sysmex America, ... urinalysis diagnostic testing equipment as well as middleware ... a way to make quality assurance easier and ... "Sysmex is well known for the innovation that ... Quality Monitor elevates quality assurance processes to a ...
Breaking Medicine Technology: